Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

NCT01599104 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1161

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: LCZ696
DRUG: Olmesartan
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals